The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.

Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V …

MeSH — NLM indexing Antiviral Agents / therapeutic use Aspartate Aminotransferases / blood Hepatitis C, Chronic / complications Humans Interferons / therapeutic use Liver Cirrhosis / blood Liver Cirrhosis / diagnosis Liver Cirrhosis / pathology Liver Cirrhosis / virology Platelet Count Predictive Value of Tests

Staff actions

Download PDF

Files are for authorised use within BioPredictive partner channels only.

Fibrotest Actitest Letter Our Group France

Authors (7)

Citation

Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismut F, et al. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology. 2004;39(3):862-3; author reply 863. doi:10.1002/hep.20099.

Identifiers

DOI: 10.1002/hep.20099
PMID: 14999708

Tests

Liver diseases

Liver injuries

Comparisons

Subjects

Region

The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.

More on the same topic

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Toward non-invasive assessment strategies in autoimmune hepatitis.

Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.